Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boston Children's Hospital
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Weill Medical College of Cornell University
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Thomas Jefferson University
Fred Hutchinson Cancer Center
AstraZeneca
Fred Hutchinson Cancer Center
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
AstraZeneca
Virginia Commonwealth University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Celgene
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
University of Alabama at Birmingham
National Cancer Institute (NCI)
Emory University
Kyntra Bio
University of Utah
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Colorado, Denver
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Reprixys Pharmaceutical Corporation
Fred Hutchinson Cancer Center
AstraZeneca
Boston Children's Hospital
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Novartis
University of Arizona
National Cancer Institute (NCI)
M.D. Anderson Cancer Center